Q2)   How did HUMIRA perform in the quarter and what are future sales
          expectations?

    A2)   Worldwide HUMIRA sales were $273 million in the quarter and
          $852 million for the full-year, exceeding our global forecast for
          2004. In the U.S., Abbott estimates that HUMIRA represents
          approximately 30 percent of new prescriptions within the self-
          injectable market for rheumatoid arthritis (RA). Based on HUMIRA's
          continued strong performance, we are raising our 2005 worldwide
          sales estimate for HUMIRA from more than $1.2 billion to more than
          $1.3 billion.

          Also in the quarter, Abbott submitted applications to regulatory
          authorities for both the HUMIRA early RA and psoriatic arthritis
          indications.